Analyst Sentiment Remains Bullish on CytomX Therapeutics (CTMX) Amid CX-2051 Therapy Progress

CytomX Therapeutics, Inc. (NASDAQ:CTMX) is one of the 12 best multibagger stocks to buy heading into 2026.

As of December 18, 2025, 90% of analysts are bullish on CytomX Therapeutics, Inc. (NASDAQ:CTMX), setting a median price target of $6.50. This translates into a healthy upside potential of 58.20%.

On December 5, 2025, CytomX Therapeutics, Inc. (NASDAQ:CTMX) saw H.C. Wainwright reiterate its “Buy” rating with a $10.00 price target, ahead of a critical data readout for the company’s CX-2051 therapy in colorectal cancer. For the upcoming dataset, the investment firm outlined clear performance benchmarks and categorized potential outcomes into “slam dunk,” “bull,” and “bear” scenarios.

Under the “slam dunk” scenario, the firm expects an objective response rate (ORR) of 25%-30% or higher, median progression-free survival (PFS) of at least six months, and Grade 3 diarrhea in fewer than 5% of patients. Meanwhile, the “bull” scenario would see an ORR of 15-20% or higher, PFS of at least five months, and Grade 3 diarrhea in fewer than 10% of patients. Lastly, the firm’s “bear case” was defined as one with an ORR of 10% or lower and a median PFS of only 2-3 months. The firm’s analysis was based on Dr. Michael Pishvaian’s inputs, who sees CX-2051’s interim performance in irinotecan-pretreated patients as particularly promising.

H.C. Wainwright’s analysis builds upon CytomX Therapeutics, Inc. (NASDAQ:CTMX)’s Q3 2025 updates that showed continued momentum on the CX-2051 program. The enrollment progressed toward approximately 100 patients ahead of the planned Phase 1 update in Q1 2026. With combination studies alongside bevacizumab set to start in the same quarter, management believes CX-2051 is well-positioned as a first-in-class EpCAM-directed ADC targeting both late-line colorectal cancer and broader EpCAM-expressing tumors.

CytomX Therapeutics, Inc. (NASDAQ:CTMX), a clinical-stage oncology company, develops conditionally activated biologics localized to tumors, including ADCs and T-cell engagers. The company aims for safer, more effective cancer therapies.

While we acknowledge the potential of CTMX as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

READ NEXT: 12 Cheap Gold Stocks to Buy Now and 15 Best AI Stocks to Watch in December 2025.

Disclosure: None.